Outlook Therapeutics (OTLK) Short term Debt (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Short term Debt of $9.8 million for Q1 2026, down 17.96% year-over-year from $12.0 million in Q1 2025, and down 73.15% quarter-over-quarter from $36.7 million in Q4 2025.
Outlook Therapeutics (OTLK) Short term Debt (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Short term Debt for 12 consecutive years, with $9.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short term Debt fell 17.96% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $9.8 million (down 17.96% YoY), while the FY2025 annual figure was $29.9 million, up 1.72% from the prior year.
- Short term Debt retreated to $9.8 million in Q1 2026 per OTLK's latest filing, from $36.7 million in the prior quarter.
- Across five years, Short term Debt topped out at $44.7 million in Q1 2024 and bottomed at $9.8 million in Q1 2026.
- Historically, Short term Debt has averaged $26.4 million across 5 years, with a median of $30.3 million in 2024.
- Annual changes were most pronounced in 2022 — Short term Debt surged 1107.15% — and 2025, when it sank 73.18%.
- Outlook Therapeutics' Short term Debt stood at $10.9 million in 2022, then surged by 234.8% to $36.5 million in 2023, then declined by 15.87% to $30.7 million in 2024, then rose by 19.24% to $36.7 million in 2025, then tumbled by 73.15% to $9.8 million in 2026.
- Business Quant data shows OTLK's Short term Debt at $9.8 million in Q1 2026, $36.7 million in Q4 2025, and $29.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.85 Mn |
| Dec 31, 2025 | 36.66 Mn |
| Sep 30, 2025 | 29.95 Mn |
| Jun 30, 2025 | 14.00 Mn |
| Mar 31, 2025 | 12.00 Mn |
| Dec 31, 2024 | 30.74 Mn |
| Sep 30, 2024 | 29.44 Mn |
| Jun 30, 2024 | 32.43 Mn |
| Mar 31, 2024 | 44.75 Mn |
| Dec 31, 2023 | 36.54 Mn |
| Sep 30, 2023 | 35.55 Mn |
| Jun 30, 2023 | 34.73 Mn |
| Mar 31, 2023 | 31.82 Mn |
| Sep 30, 2022 | 10.92 Mn |
| Jun 30, 2022 | 10.46 Mn |
| Mar 31, 2022 | 22.78 Mn |
| Dec 31, 2021 | 12.72 Mn |
| Sep 30, 2021 | 904,200.00 |
| Jun 30, 2021 | 11.55 Mn |
| Mar 31, 2021 | 11.18 Mn |